| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
| Targets |
Cystathionine-γ-lyase-IN-1 targets cystathionine γ-lyase (CSE), a key enzyme in the transsulfuration pathway that catalyzes the conversion of cystathionine to cysteine, producing hydrogen sulfide (H₂S) as a byproduct. By inhibiting CSE, the compound reduces H₂S production, which is involved in various physiological processes including vasorelaxation, inflammation, and cytoprotection. The compound completely abrogates L-cysteine-induced vasorelaxation at 100 μM, confirming its functional activity.
|
|---|---|
| ln Vitro |
Cystathionine-γ-lyase-IN-1 (compound 2a) totally eliminates the vasodilation caused by L-cysteine when diluted to 100 μM [1]. The L-Cys-stimulated rise in H2S generation in mouse aortic homogenates is considerably inhibited by cystathionine-γ-lyase-IN-1 (100 μM; 30 minutes) [1].
In vitro, Cystathionine-γ-lyase-IN-1 selectively inhibits CSE with an IC50 of 6.3 μM. At 100 μM, the compound completely abrogates L-cysteine-induced vasorelaxation, confirming its functional activity in a relevant biological assay. The compound's alkyne group allows for click chemistry applications, including conjugation to azide-containing molecules for target identification and imaging studies. |
| ln Vivo |
Specific in vivo data for Cystathionine-γ-lyase-IN-1 are limited. As a CSE inhibitor, the compound would have potential for in vivo studies in models of cardiovascular disease, inflammation, and conditions where H₂S signaling is implicated. The compound's ability to abrogate L-cysteine-induced vasorelaxation in vitro suggests potential for studying vasoregulation in vivo. However, specific published in vivo protocols for this compound are not detailed.
|
| Enzyme Assay |
The CSE inhibitory activity is assessed using biochemical enzyme assays. Recombinant CSE enzyme is incubated with the substrate L-cystathionine and various concentrations of Cystathionine-γ-lyase-IN-1. The production of cysteine or H₂S is measured using colorimetric, fluorometric, or HPLC methods. IC50 values are calculated from dose-response curves. For click chemistry applications, the compound's alkyne group is reacted with azide-containing probes under copper-catalyzed conditions.
|
| Cell Assay |
For cellular studies, cells expressing CSE (e.g., vascular smooth muscle cells, hepatocytes) are cultured in appropriate media. Cells are treated with Cystathionine-γ-lyase-IN-1 at various concentrations (e.g., 1-100 μM) for 24-72 hours. CSE activity is measured in cell lysates using substrate conversion assays. H₂S levels are measured using fluorescent probes (e.g., WSP-1). Cell viability is assessed using MTT or similar assays. The compound is typically dissolved in DMSO and diluted in culture media.
|
| Animal Protocol |
In vivo studies for Cystathionine-γ-lyase-IN-1 would be conducted in appropriate animal models. For cardiovascular research, models of hypertension or ischemia-reperfusion injury would be used. For inflammation research, models of LPS-induced systemic inflammation or colitis would be employed. The compound would be administered via oral gavage or intraperitoneal injection. However, specific published protocols for this compound are not available.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Cystathionine-γ-lyase-IN-1 are not reported. The compound has a molecular weight of 184.22 g/mol and a molecular formula of C₇H₈N₂O₂S. Its small size and alkyne functionality may facilitate cellular uptake and labeling applications. Pharmacokinetic studies would be required to determine parameters such as half-life, Cmax, and bioavailability. The compound is typically stored as a powder at -20°C.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for Cystathionine-γ-lyase-IN-1 are not reported. As a research compound, comprehensive toxicology studies including acute, subchronic, and genotoxicity assessments have not been reported. The compound should be handled with appropriate safety precautions in laboratory settings. As a CSE inhibitor that modulates H₂S production, potential effects on cardiovascular and inflammatory pathways should be considered.
|
| References |
[1]. Angela Corvino, et al. Fragment-based de novo design of a cystathionine γ-lyase selective inhibitor blocking hydrogen sulfide production. Sci Rep. 2016 Oct 6;6:34398.
|
| Additional Infomation |
Cystathionine-γ-lyase-IN-1 is a selective CSE inhibitor with an IC50 of 6.3 μM. It contains an alkyne group for click chemistry applications and completely abrogates L-cysteine-induced vasorelaxation at 100 μM. No clinical trials exist. For research use only.
|
| Molecular Formula |
C7H8N2O2S
|
|---|---|
| Molecular Weight |
184.215620040894
|
| Exact Mass |
184.03
|
| CAS # |
2165706-30-7
|
| PubChem CID |
124221753
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-0.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
12
|
| Complexity |
255
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C#CCNC(=O)[C@@H]1CSC(=O)N1
|
| InChi Key |
MWEQVHWJNCRXGP-YFKPBYRVSA-N
|
| InChi Code |
InChI=1S/C7H8N2O2S/c1-2-3-8-6(10)5-4-12-7(11)9-5/h1,5H,3-4H2,(H,8,10)(H,9,11)/t5-/m0/s1
|
| Chemical Name |
(4R)-2-oxo-N-prop-2-ynyl-1,3-thiazolidine-4-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~18 mg/mL (~97.71 mM)
Ethanol : ~9 mg/mL (~48.85 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4283 mL | 27.1415 mL | 54.2829 mL | |
| 5 mM | 1.0857 mL | 5.4283 mL | 10.8566 mL | |
| 10 mM | 0.5428 mL | 2.7141 mL | 5.4283 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
